Initial Public Offering
Baird served as a co-manager on this offering
AboutAblynx NV (“Ablynx” or the “Company”) (Euronext Brussels and NASDAQ-GS: ABLX), a late-stage clinical biopharmaceutical company utilizing its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need, recently completed an initial United States public offering totaling $230.0 million gross proceeds from the sale of 13,144,500 ordinary shares in the form of American Depositary Shares ("ADSs") at a price of $17.50 per ADS, before underwriting discounts. The net proceeds are estimated at $210.2 million and include the full exercise of the underwriters’ option to purchase additional ADSs.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. Ablynx has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, United States; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
CONTACT US TO LEARN MORE
- October 2017
- Ablynx NV
- Target Location